{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:00:09Z","timestamp":1776056409181,"version":"3.50.1"},"reference-count":56,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Keimzelltumore sind die h\u00e4ufigsten Tumorentit\u00e4ten bei jungen M\u00e4nnern. Seit der Einf\u00fchrung\n      der platinbasierten Chemotherapie in den 1970er-Jahren k\u00f6nnen die meisten Patienten trotz der\n      Aggressivit\u00e4t der Keimzelltumoren kurativ behandelt werden. F\u00fcr Diagnostik, Therapiemonitoring\n      und Nachsorge werden m\u00f6glichst optimale Serumtumormarker ben\u00f6tigt, an die hohe Anforderungen\n      gestellt werden. Die konventionellen Hodentumormarker humanes Choriongonadotropin (hCG),\n      Alpha-Fetoprotein (AFP) und Laktatdehydrogenase (LDH) werden diesen Anforderungen nur mit\n      einer unzureichenden Sensitivit\u00e4t gerecht (30\u201370%). Die in den letzten Jahrzehnten\n      untersuchten Marker wie PLAP, CEA und NSE haben sich nicht durchgesetzt. Aktuell wird\n      besonders die miRNA-371 erforscht. Gesicherte Erkenntnisse liegen vor f\u00fcr das initiale Staging\n      mit deutlich besseren Spezifit\u00e4ten der miRNA-371 im Vergleich zu den konventionellen\n      Tumormarkern. F\u00fcr weitere m\u00f6gliche klinische Einsatzgebiete wie der Nachsorge, dem\n      Therapiemonitoring oder bei Residualtumoren erfolgen weitere prospektive Studien, um auch hier\n      das revolution\u00e4re Potenzial der miRNA-371 zu untersuchen. Weiterhin wird aktuell an\n      zirkulierenden Tumorzellen (CTCs) und zellfreier DNA (cfNA) in verschiedenen\n      Anwendungsgebieten geforscht. In Bezug auf Keimzelltumore des Hodens stehen diese Analysen\n      jedoch noch am Anfang, aber man erhofft sich hiervon eine weitere suffiziente M\u00f6glichkeit\n      Serumtumormarker einzusetzen.<\/jats:p>","DOI":"10.1055\/a-2422-0354","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T22:45:41Z","timestamp":1729723541000},"page":"520-527","source":"Crossref","is-referenced-by-count":2,"title":["Neue Tumormarker bei Hodentumoren \u2013 im hier und jetzt und in der Zukunft"],"prefix":"10.1055","volume":"55","author":[{"given":"Justine","family":"Schoch","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Urologie, Bundeswehrzentralkrankenhaus Koblenz, Koblenz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Schmelz","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Urologie, Bundeswehrzentralkrankenhaus Koblenz, Koblenz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3821-7956","authenticated-orcid":false,"given":"Klaus-Peter","family":"Dieckmann","sequence":"additional","affiliation":[{"name":"Urologie, Asklepios Klinik Altona, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6033-6364","authenticated-orcid":false,"given":"Tim","family":"Nestler","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Urologie, Bundeswehrzentralkrankenhaus Koblenz, Koblenz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"ref2","doi-asserted-by":"publisher","first-page":"e070499","DOI":"10.1136\/bmj-2022-070499","article-title":"Advances in diagnosis and treatment of testicular cancer","volume":"379","author":"M Chovanec","year":"2022","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","article-title":"International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers","volume":"15","author":"International Germ Cell Cancer Collaborative Group","year":"1997","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000510407","article-title":"Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages","volume":"105","author":"S Kliesch","year":"2021","journal-title":"Urol Int"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/j.clgc.2017.08.018","article-title":"Non-Guideline-concordant Treatment of Testicular Cancer Is Associated With Reduced Relapse-free Survival","volume":"6","author":"P Paffenholz","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/his.14675","article-title":"An introduction to the WHO 5th edition 2022 classification of testicular tumours","volume":"81","author":"DM Berney","year":"2022","journal-title":"Histopathology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00432-019-02844-z","article-title":"Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment","volume":"145","author":"CD Fankhauser","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"16829","DOI":"10.1002\/cam4.6304","article-title":"Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment","volume":"12","author":"M Majewski","year":"2023","journal-title":"Cancer Med"},{"issue":"S 03","key":"ref9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/1097-0142(19870801)60:3+<464::aid-cncr2820601506>3.0.co;2-c","article-title":"Biological markers in urologic cancer","volume":"60","author":"PH Lange","year":"1987","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1200\/JCO.2004.04.008","article-title":"Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors","volume":"22","author":"K Fizazi","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.eururo.2010.12.010","article-title":"Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience","volume":"59","author":"JF Sturgeon","year":"2011","journal-title":"Eur Urol"},{"key":"ref12","first-page":"274","article-title":"Maligne Hodentumoren und Hypophysenvorderlappenhormone. Hormonale Diagnostik aus Harn, Hydrocelenfl\u00fcssigkeit und Tumorgewebe","volume":"11","author":"B Zondek","year":"1932","journal-title":"Klinische Wochenschr"},{"key":"ref13","first-page":"209","article-title":"Immunochemical determination of human chorionic gonadotropin and alpha-fetoprotein in sera and tumors of patients with testicular cancer","volume":"49","author":"N Javadpour","year":"1978","journal-title":"Natl Cancer Inst Monogr"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841868409136024","article-title":"Tumour markers in testicular germ cell tumours. Five-year experience from the DATECA Study 1976\u20131980","volume":"23","author":"B Norgaard-Pedersen","year":"1984","journal-title":"Acta Radiol Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"5030349","DOI":"10.1155\/2019\/5030349","article-title":"Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment","volume":"2019","author":"KP Dieckmann","year":"2019","journal-title":"Biomed Res Int"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ucl.2022.09.002","article-title":"Biomarkers in Testicular Cancer: Classic Tumor Markers and Beyond","volume":"50","author":"J Egan","year":"2023","journal-title":"Urol Clin North Am"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ucl.2015.08.011","article-title":"Current Clinical Applications of Testicular Cancer Biomarkers","volume":"43","author":"MC Mir","year":"2016","journal-title":"Urol Clin North Am"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00432-017-2520-5","article-title":"The usefulness of testosterone administration in identifying false-positive elevation of serum human chorionic gonadotropin in patients with germ cell tumor","volume":"144","author":"A Takizawa","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000225681","article-title":"Evaluation of five tumor markers (AFP, CEA, hCG, hPL and SP1) in monitoring therapy and follow-up of patients with testicular germ cell tumors","volume":"40","author":"JJ Szymendera","year":"1983","journal-title":"Oncology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/1097-0142(19870901)60:5<1017::aid-cncr2820600516>3.0.co;2-d","article-title":"Serum neuron-specific enolase. A marker for responses to therapy in seminoma","volume":"60","author":"R Kuzmits","year":"1987","journal-title":"Cancer"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/ijc.10459","article-title":"Clinical use of serum TRA-1\u201360 as tumor marker in patients with germ cell cancer","volume":"100","author":"H Lajer","year":"2002","journal-title":"Int J Cancer"},{"key":"ref22","first-page":"311","article-title":"Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer","volume":"42","author":"A Neumann","year":"2011","journal-title":"Aktuelle Urol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/0277-5379(90)90049-y","article-title":"Is placental alkaline phosphatase (PLAP) a useful marker for seminoma?","volume":"26","author":"OS Nielsen","year":"1990","journal-title":"Eur J Cancer"},{"key":"ref24","first-page":"5029","article-title":"Tu-M2-PK in the blood of testicular and cubital veins in men with testicular cancer","volume":"20","author":"T Pottek","year":"2000","journal-title":"Anticancer Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/ijms20020258","article-title":"Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic","volume":"20","author":"J Lobo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1387\/ijdb.130020re","article-title":"Role of stem cell proteins and microRNAs in embryogenesis and germ cell cancer","volume":"57","author":"R Eini","year":"2013","journal-title":"Int J Dev Biol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ydbio.2004.02.019","article-title":"Human embryonic stem cells express a unique set of microRNAs","volume":"270","author":"MR Suh","year":"2004","journal-title":"Dev Biol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/path.2230","article-title":"High-throughput microRNAome analysis in human germ cell tumours","volume":"213","author":"AJ Gillis","year":"2007","journal-title":"J Pathol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.juro.2014.07.010","article-title":"Circulating serum miRNA (miR-367\u20133p, miR-371a-3p, miR-372\u20133p and miR-373\u20133p) as biomarkers in patients with testicular germ cell cancer","volume":"193","author":"I Syring","year":"2015","journal-title":"J Urol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"58037","DOI":"10.18632\/oncotarget.10867","article-title":"Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test)","volume":"8","author":"T van Agthoven","year":"2017","journal-title":"Oncotarget"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.eururo.2016.07.029","article-title":"Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours","volume":"71","author":"KP Dieckmann","year":"2017","journal-title":"Eur Urol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1007\/s00432-017-2490-7","article-title":"Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?","volume":"143","author":"A Radtke","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.3390\/cancers15153944","article-title":"MicroRNA-371a-3p-The Novel Serum Biomarker in Testicular Germ Cell Tumors","volume":"15","author":"T Nestler","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00261-019-02395-4","article-title":"Imaging of scrotal masses","volume":"45","author":"KG Sharbidre","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1078-0432.CCR-23-0730","article-title":"Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study","volume":"30","author":"G Belge","year":"2024","journal-title":"Clin Cancer Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.euo.2020.11.004","article-title":"Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer","volume":"4","author":"J Lobo","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000488771","article-title":"The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1","volume":"100","author":"A Radtke","year":"2018","journal-title":"Urol Int"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/cells8101221","article-title":"miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy","volume":"8","author":"X Rosas Plaza","year":"2019","journal-title":"Cells"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1002\/cncr.33051","article-title":"Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications","volume":"126","author":"EC Umbreit","year":"2020","journal-title":"Cancer"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/JU.0000000000003812","article-title":"Adjunctive Surgery Is Often Without Oncological Benefit at Time of Postchemotherapy Retroperitoneal Lymph Node Dissection","volume":"211","author":"T Nestler","year":"2024","journal-title":"J Urol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.eururo.2012.08.014","article-title":"Contemporary management of postchemotherapy testis cancer","volume":"62","author":"S Daneshmand","year":"2012","journal-title":"Eur Urol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"809 e9\u2013e18","DOI":"10.1016\/j.urolonc.2019.07.021","article-title":"External validation of 2 models to predict necrosis\/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer","volume":"37","author":"P Paffenholz","year":"2019","journal-title":"Urol Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.18.01480","article-title":"Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study","volume":"37","author":"KP Dieckmann","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.05.002","article-title":"Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours","author":"KP Dieckmann","year":"2024","journal-title":"Eur Urol Focus"},{"key":"ref45","isbn-type":"print","volume-title":"EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023","ISBN":"https:\/\/id.crossref.org\/isbn\/9789492671196"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of Cell-free DNA Analysis to Cancer Treatment","volume":"379","author":"RB Corcoran","year":"2018","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.juro.2008.08.118","article-title":"Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer","volume":"181","author":"J Ellinger","year":"2009","journal-title":"J Urol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221090365","article-title":"The utility of cfDNA in TGCT patient management: a systematic review","volume":"14","author":"J Krasic","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"C Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/s1470-2045(02)00776-3","article-title":"An oncological view on the blood-testis barrier","volume":"3","author":"J Bart","year":"2002","journal-title":"Lancet Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3390\/cancers12092361","article-title":"Circulating Tumor Cells: From the Laboratory to the Cancer Clinic","volume":"12","author":"R Agashe","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-019-0735-4","article-title":"Technologies for circulating tumor cell separation from whole blood","volume":"12","author":"P Banko","year":"2019","journal-title":"J Hematol Oncol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2018.01.002","article-title":"Size-based separation methods of circulating tumor cells","volume":"125","author":"SJ Hao","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"M Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"473","DOI":"10.21037\/tlcr.2017.05.08","article-title":"Biophysical technologies for understanding circulating tumor cell biology and metastasis","volume":"6","author":"DW Su","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1126\/science.1235226","article-title":"Cancer. Circulating tumor cells","volume":"341","author":"V Plaks","year":"2013","journal-title":"Science"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1158\/1078-0432.CCR-13-2819","article-title":"Circulating tumor cells in patients with testicular germ cell tumors","volume":"20","author":"P Nastaly","year":"2014","journal-title":"Clin Cancer Res"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2422-0354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T23:37:09Z","timestamp":1733269029000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2422-0354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":56,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2024,12,3]]},"published-print":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2422-0354","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}